Understanding Immune Effector Cell-Associated Enterocolitis After CAR T-Cell Therapy

In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD, BCOP, clinical pharmacy specialist with Stem Cell Transplantation and Cellular Therapy Department at The University of Texas MD Anderson Cancer Center and current ASTCT director of pharmacists (ex-officio) and Mark Hamilton, MD, of The University of Texas MD Anderson Cancer Center discuss immune effector cell-associated enterocolitis (IEC-EC), a rare but potentially severe late complication of BCMA-directed CAR T-cell therapy. As the use of CAR T-cell therapies continues to expand, understanding and managing delayed toxicities has become increasingly important. The discussion highlights: - The clinical presentation, incidence, and risk factors associated with IEC-EC. - Current approaches to diagnosis, including endoscopy, pathology evaluation, and detection of CAR T-cell infiltration in the gastrointestinal tract. - Emerging insights into the biology of IEC-EC and the role of persistent CAR T cells. - Treatment strategies, supportive care considerations, and areas of ongoing research. This episode provides valuable clinical and translational perspectives on a rare but important CAR T-cell-related toxicity and explores how ongoing research may help improve diagnosis, management, and patient outcomes. Listen to the episode below or on your favorite app. Subscribe to ASTCT Talks and share this episode with your colleagues to keep the conversation going. *This episode was made possible through support from Johnson & Johnson.*